AAV Gene Therapy Yields Further Hearing Improvements in Congenital Deafness Patients

A clinical trial published June 26, 2026 in Nature Medicine found that re-administering AAV gene therapy to four patients with congenital deafness—despite preexisting neutralizing antibodies—was safe and led to further hearing improvements. The study marks a demonstration that immune responses to AAV vectors do not necessarily block repeat dosing in gene therapy for OTOF-related hearing loss, raising potential for long-term treatment strategies.

The four patients, aged 12 to 25, had previously received a first gene therapy dose and developed neutralizing antibodies, which typically reduce the effectiveness of AAV-based therapies. When researchers re-administered the therapy using a different AAV serotype (AAV9), three patients showed measurable hearing improvements, while one showed stabilization of hearing levels. The study authors emphasized that the re-dosing approach avoided serious adverse events, with only mild, transient reactions reported.

The findings build on prior work showing AAV-mediated gene therapy can restore hearing in patients with OTOF-related deafness, a genetic condition caused by mutations in the OTOF gene. A 2023 study in The Lancet demonstrated that a single dose of AAV1-OTOF could improve hearing in children, but the development of neutralizing antibodies had been a major hurdle for repeat treatments. This new trial suggests that switching AAV serotypes may circumvent immune barriers, potentially allowing for multiple doses to sustain or enhance therapeutic effects over time.

Why does this matter?
The ability to re-administer gene therapy without triggering severe immune reactions could transform treatment for rare genetic disorders where a single dose is insufficient to maintain long-term benefits. For OTOF-related deafness, which affects approximately 1 in 100,000 individuals, current options are limited to hearing aids or cochlear implants. Gene therapy offers a potential cure, but the challenge of immune responses has been a critical roadblock. The Nature Medicine trial suggests that serotype switching—a strategy already explored in other AAV-based therapies—could be a viable solution.

How does AAV serotype switching work?
AAV vectors come in different serotypes (e.g., AAV1, AAV2, AAV9), each with distinct immune profiles. In this trial, researchers used AAV9 for the second dose, a serotype less likely to trigger cross-reactive antibodies compared to AAV1. While three patients showed hearing improvements, the fourth experienced no further gain, highlighting that individual immune responses vary. The study did not explore why one patient did not respond, but the authors noted that further research is needed to optimize dosing schedules and serotype selection.

What comes next?
The trial’s small size and single-arm design limit its conclusions, but the results have prompted calls for larger, controlled studies. A team is planning a follow-up trial to assess long-term safety and efficacy of repeat dosing in a broader patient group. Meanwhile, other researchers are investigating whether combining AAV therapies with immunosuppressive drugs could further reduce immune rejection risks. The U.S. Food and Drug Administration has not yet reviewed these findings, but the data could influence future gene therapy guidelines for genetic hearing loss.

Key uncertainties remain
While the trial is promising, critical questions persist. First, the long-term durability of hearing improvements after re-dosing is unknown—patients in this study were followed for only 12 months. Second, the cost and feasibility of switching AAV serotypes in clinical practice have not been evaluated. Finally, the broader applicability of this approach to other genetic disorders requiring repeat gene therapy remains untested. The study authors acknowledge these limitations but emphasize that the lack of severe adverse events in this small cohort is a critical first step.

For patients with OTOF-related deafness, the trial offers cautious hope. While gene therapy is not yet a standard treatment, these results suggest that overcoming immune barriers may be possible, potentially paving the way for sustained hearing restoration. The next phase will determine whether this approach can be scaled safely and effectively.